Abstract
Background Automated classification of glomerular pathological findings is potentially beneficial in establishing an efficient and objective diagnosis in renal pathology. While previous studies have verified the artificial intelligence (AI) models for the classification of global sclerosis and glomerular cell proliferation, there are several other glomerular pathological findings required for diagnosis, and the comprehensive models for the classification of these major findings have not yet been reported. Whether the cooperation between these AI models and clinicians improves diagnostic performance also remains unknown. Here, we developed AI models to classify glomerular images for major findings required for pathological diagnosis and investigated whether those models could improve the diagnostic performance of nephrologists.
Methods We used a dataset of 283 kidney biopsy cases comprising 15888 glomerular images that were annotated by a total of 25 nephrologists. AI models to classify seven pathological findings: global sclerosis, segmental sclerosis, endocapillary proliferation, mesangial matrix accumulation, mesangial cell proliferation, crescent, and basement membrane structural changes, were constructed using deep learning by fine-tuning of InceptionV3 convolutional neural network. Subsequently, we compared the agreement to truth labels between majority decision among nephrologists with or without the AI model as a voter.
Results Our model for global sclerosis showed high performance (area under the curve: periodic acid-Schiff, 0.986; periodic acid methenamine silver, 0.983); the models for the other findings also showed performance close to those of nephrologists. By adding the AI model output to majority decision among nephrologists, the sensitivity and specificity were significantly improved in 9 of 14 constructed models compared to those of nephrologists alone.
Conclusion Our study showed a proof-of-concept for the classification of multiple glomerular findings in a comprehensive method of deep learning and suggested its potential effectiveness in improving diagnostic accuracy of clinicians.
Competing Interest Statement
E. Uchino and Y. Tamada were given a budget for a joint research project with Fujitsu Ltd. M. Yanagita received research grants from Astellas, Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma Corporation, MSD, Baxter, Takeda Pharmaceutical, KISSEI PHARMACEUTICAL, Dainippon Sumitomo Pharma, TAISHO TOYAMA PHARM, and Torii. The other authors declare no conflicts of interest.
Funding Statement
This research was conducted as a joint research project and used funds from Kyoto University and Fujitsu Ltd. This work was also supported by the JSPS KAKENHI Grant Number JP18H05959. This research was partly conducted under collaborative research program with RIKEN. This research was partly supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP18gm5010002 and by World Premier International Research Center Initiative (WPI), MEXT, Japan.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our data is not available because we have no permission to open our data.
